Linezolid Hikma

Linezolid, the active ingredient in Linezolid Hikma, is an oxazolidinone presented as an intravenous solution for intravenous use. It is indicated for serious infections caused by resistant Gram‑positive bacteria, including methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE), as well as for certain cases of community‑acquired and hospital‑acquired pneumonia and skin‑soft‑tissue infections in adult patients.

GNH USA supplies Linezolid Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this essential antibacterial agent for qualified healthcare providers.

Linezolid is used to treat infections caused by resistant Gram‑positive bacteria, particularly in the skin, respiratory and systemic compartments.

- Methicillin‑resistant Staphylococcus aureus (MRSA) infections: eradicates the pathogen and resolves systemic or localized disease. - Vancomycin‑resistant Enterococcus (VRE) infections: provides an effective alternative when vancomycin is ineffective. - Community‑acquired and hospital‑acquired pneumonia: clears bacterial load and improves respiratory function. - Skin and soft‑tissue infections: eliminates resistant organisms and promotes wound healing.

Adverse reactions may occur with linezolid therapy.

Common Side Effects: - Nausea - Diarrhea - Headache - Metallic taste

Serious or Rare Side Effects: - Thrombocytopenia - Peripheral neuropathy - Serotonin syndrome

Use linezolid with appropriate clinical monitoring and awareness of specific risk factors.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: assess liver enzymes regularly during treatment. - Hematologic monitoring: obtain baseline and periodic complete blood counts. - Concomitant serotonergic agents: avoid due to risk of serotonin syndrome. - Pregnancy and lactation: prescribe only when benefits outweigh potential risks. - Store at ambient temperature: keep in original container, protect from light and moisture.

Linezolid may interact with several drug classes; careful assessment is required.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension and serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) and SNRIs: increase chance of serotonin syndrome. - Rifampin: markedly reduces linezolid plasma concentrations. - Erythromycin: may increase linezolid exposure and toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, requiring frequent monitoring. - Phenytoin: may lower linezolid levels, reducing efficacy. - Carbamazepine: can decrease linezolid concentrations, necessitating dose review.